Fetoscopic NEOX Cord 1K® Spina Bifida Repair

NCT ID: NCT04243889

Last Updated: 2025-09-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-28

Study Completion Date

2029-03-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To fetoscopically use cryopreserved human umbilical cord allografts, named NEOX Cord 1K®, as a spinal cord cover of spina bifida defects. This procedure will be performed to create a watertight seal covering over the spinal cord in order to decrease the incidence rates of postnatal morbidities. For larger skin defects, NEOX Cord 1K® may be used as a skin cover.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spina Bifida Myelomeningocele Myeloschisis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NEOX Cord 1K applied fetoscopically

Patients intending to undergo open in-utero spina bifida repair, will be offered to be screened for an alternative minimally invasive approach. All eligible pregnant mothers' fetuses within the trial will receive NEOX Cord 1K® as a spinal cord cover to close the developmental defect. In some cases, at the discretion of the Neurosurgeon, NEOX Cord 1K® may be required to cover the skin. All eligible subjects meeting all inclusion criteria but none of the exclusion criteria may be enrolled.

Group Type EXPERIMENTAL

NEOX Cord 1K

Intervention Type DEVICE

Under general anesthesia and tocolysis, in-utero repair begins with a laparotomy that is followed by exteriorization of the uterus. The fetus is then positioned by external cephalic version. Uterine entry will be accessed using 3 cannulas, followed by heated-humidified carbon dioxide insufflation for visualization. Then, fetoscopically the placode will be examined and dissected. The lesion will be repaired using NEOX Cord 1K® (HUC) for closure of the first layer over the neural placode. Primary closure of the skin will then occur, or NEOX Cord 1K® (HUC) will be used for skin closure at the discretion of the neurosurgeon. Finally, the laparotomy site will be sutured in multiple layers.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NEOX Cord 1K

Under general anesthesia and tocolysis, in-utero repair begins with a laparotomy that is followed by exteriorization of the uterus. The fetus is then positioned by external cephalic version. Uterine entry will be accessed using 3 cannulas, followed by heated-humidified carbon dioxide insufflation for visualization. Then, fetoscopically the placode will be examined and dissected. The lesion will be repaired using NEOX Cord 1K® (HUC) for closure of the first layer over the neural placode. Primary closure of the skin will then occur, or NEOX Cord 1K® (HUC) will be used for skin closure at the discretion of the neurosurgeon. Finally, the laparotomy site will be sutured in multiple layers.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Singleton pregnancy
* Gestational age at screening is 19 to 25 5/7 weeks and gestational age at surgery is 22 to 25 6/7 weeks
* Maternal age: 18 years and older
* Body mass index \< 40 kg/m2
* No preterm birth risk factors (short cervix, history of previous preterm delivery)
* No previous uterine incision in the active uterine segment
* Willing to undergo an open fetal repair if the fetoscopic approach is unsuccessful


* Spina bifida defect between T1 to S1 vertebral levels
* Chiari II malformation
* No evidence of kyphosis (curved spine)
* No major life-threatening fetal anomaly unrelated to spina bifida
* Normal karyotype, or normal Chromosomal microarray analysis (CMA), or a CMA with variants of unknown significance

Exclusion Criteria

* Non-resident of the United States
* Multifetal pregnancy
* Poorly controlled insulin-dependent pregestational diabetes
* Poorly controlled A2 diabetes mellitus (A2DM) insulin-dependent diabetes
* Current or planned cerclage or documented history of an incompetent cervix
* Placenta previa or placental abruption
* Short cervix of \< 20 mm
* Obesity as defined by a body mass index of \> 40 kg/m2
* Previous spontaneous singleton delivery prior to 37 weeks
* Maternal-fetal Rh isoimmunization, Kell sensitization, or a history of neonatal alloimmune thrombocytopenia
* HIV or Hepatitis-B positive status
* Known Hepatitis-C positivity
* Uterine anomaly such as large or multiple fibroids or a mullerian duct abnormality that is diagnosed via imaging prior to surgery, which that are unavoidable during surgery
* Other medical conditions which are contraindication to surgery or general anesthesia
* Patient does not have a support person
* Inability to comply with the travel and follow-up requirements of the trial
* Patient does not meet psychosocial standardized assessment criteria
* Participation in this or another intervention study that influences maternal and fetal morbidity and mortality
* Maternal hypertension
* Zika virus positivity
* Allergy/history of drug reaction to Amphotericin B


* Major fetal anomaly not related to spina bifida
* Kyphosis in the fetus of 30 degrees or more
* Ventriculomegaly greater than 15 mm and no movements noted at hip and knee joints
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The University of Texas Health Science Center, Houston

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ramesha Papanna

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ramesha Papanna, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

The University of Texas Health Science Center, Houston

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The University of Texas Health Science Center at Houston

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Backley S, Bergh EP, Garnett J, Li R, Maroufy V, Jain R, Fletcher S, Tsao K, Austin M, Johnson A, Papanna R. Fetal cardiovascular changes during open and fetoscopic in-utero spina bifida closure. Ultrasound Obstet Gynecol. 2024 Aug;64(2):193-202. doi: 10.1002/uog.27579.

Reference Type DERIVED
PMID: 38207160 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HSC-MS-19-1051

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

rhBMP-2 in Cervical Arthrodesis
NCT02178605 COMPLETED
IO Vancomycin Spine
NCT06748144 NOT_YET_RECRUITING PHASE2/PHASE3
Spinal Fusions Steroid Study
NCT05287035 UNKNOWN EARLY_PHASE1